Roche: receives CE mark for its cobas solution
(CercleFinance.com) - Roche announced today that it has received CE marking for its cobas Mass Spec solution, comprising the cobas i 601 analyzer and the first four-assay Ionify reagent pack for steroid hormones.
CE marking is the first step in the global launch of the cobas Mass Spec solution, which uses an in-house innovation to bring automated clinical mass spectrometry testing to the market.
Following launch, the cobas Mass Spec solution will offer a menu of over 60 analytes for testing steroid hormones, vitamin D metabolites, immunosuppressive drugs (ISD), therapeutic drug monitoring (TDM) and drug testing (DAT).
The cobas Mass Spec solution will revolutionize the field of clinical diagnostics, said Matt Sause, CEO of Roche Diagnostics.
This solution would make fully standardized clinical mass spectrometry more widely available and improve patient care worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
CE marking is the first step in the global launch of the cobas Mass Spec solution, which uses an in-house innovation to bring automated clinical mass spectrometry testing to the market.
Following launch, the cobas Mass Spec solution will offer a menu of over 60 analytes for testing steroid hormones, vitamin D metabolites, immunosuppressive drugs (ISD), therapeutic drug monitoring (TDM) and drug testing (DAT).
The cobas Mass Spec solution will revolutionize the field of clinical diagnostics, said Matt Sause, CEO of Roche Diagnostics.
This solution would make fully standardized clinical mass spectrometry more widely available and improve patient care worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.